Ticagrelor is a selective, direct-acting inhibitor of the P2Y12 ADP-receptor on platelets, used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It reversibly binds to the P2Y12 receptor, preventing ADP-induced platelet aggregation and thereby inhibiting thrombus formation. This leads to decreased rates of cardiovascular death, myocardial infarction, and stroke. Administered orally as a tablet, typically in combination with low-dose aspirin for chronic therapy.